Federated Simulation Intelligence

Forecast the whole network. Expose nothing.

SimSumNexus is the federated simulation layer for regulated supply chains. Partners contribute anonymized, signed signals; everyone receives sealed forecasts of downstream effects — without anyone exposing raw data.

Beachhead
Pharma & biologics cold chain
Model
Privacy-preserving simulation
Stage
Seed · 2026
Scroll
01The problem

Everyone who could see the disruption coming is holding one piece of the picture.

Pharma and biologics cold chains run many companies deep — manufacturers, CDMOs, distributors, 3PLs, carriers, insurers. None will share proprietary volumes, lanes, or forecasts. So everyone forecasts blind, on their own slice of reality.

95%+
of biologics depend on an unbroken cold chain
~50%
of vaccines wasted globally, much to temperature excursions
1
cell & gene shipment is a batch of one — no backup, no second chance
02The platform

Four layers turn private signals into shared foresight.

Contribute without exposing. Simulate across the network, not just your four walls. Receive a sealed decision — not another dashboard.

/ 01

Signal Gateway

Partners contribute minimized, signed signals at the edge. Designed for selective disclosure, time-bounded validity, and revocation — raw records never leave the contributor.

/ 02

Nexus Ontology

One shared, federated model of the network — lanes, nodes, dependencies — assembled from contributions without reconstructing any single party's book of business.

/ 03

Simulation Fabric

Forecast downstream effects across mutually-distrustful parties: where a shock propagates, what fails next, and how much runway remains before it reaches you.

/ 04

Outcome Briefings

The output is a sealed briefing — a ranked, explainable decision with its rationale — delivered to the parties entitled to see it, and no one else.

03The instrument

This isn't a promise. It's running.

The Nexus Suite — Control Tower, Risk Intelligence, Network Graph, and Analytics — as a working, interactive prototype on synthetic data. What you see below is the specification v1.0 is being built to.

Nexus Suite Control Tower — tactical world map with live lanes, exception feed, and ranked action items
Control Tower — tactical network view · live lanes · exceptions · action items
Risk Intelligence — disruption propagation forecast with decision runway
Risk Intelligence — propagation forecast · decision runway
Network Graph — the Nexus Ontology as a structured, functional network model
Network Graph — the ontology, structured by function

Interactive prototype on synthetic data — drag the map, run the simulation, seal a briefing. Trust Fabric mechanisms shown are design intent for v1.0.

04Why it holds

Palantir gives you a telescope for your own yard. We let the whole street see the storm — without anyone opening their blinds.

Federated by default

No central data lake to breach or subpoena. Intelligence is computed across the network; raw data stays with its owner.

Privacy-preserving

Designed around signed, minimized signals, selective disclosure, and differential privacy — contribution never means exposure.

Simulation-first

Not a read-only risk score. A forward model that plays the disruption forward and tells you what to do about it.

Pharma-native, mid-market priced

Built for the regulated cold chain under DSCSA tailwinds — and reachable by the tier no incumbent serves.

No incumbent holds this intersection — not Palantir, Altana, Interos, project44, or TraceLink. The privacy primitives above describe the architecture SimSumNexus is designed for; v1.0 ships before the raise.

05The opportunity

A category forming at the intersection of two markets racing upward.

$44B
pharma cold chain by the early 2030s, up from ~$22.75B
~21%
CAGR in supply-chain risk software — ~$8B heading toward $50B+
$2.0M
seed — 18–24 months to first contracts and a fundable Series A

Anonymized signals · Actionable outcomes

See it coming — without opening your blinds.

A controlled briefing walks your team through the wedge, the architecture, and the path to v1.0. Founder-led, AI-augmented, pharma-native.